Aldeyra Therapeutics, Inc. ALDX
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Aldeyra Therapeutics, Inc. (ALDX) is a healthcare company listed in the US with a market value of about $39M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -36%.
About Aldeyra Therapeutics
Aldeyra Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. It was profitable in 0 of the last 10 years in our data. Its share count rose by 3% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$34M | -$56M | -$38M | -$62M | -$58M | -$38M | -$61M | -$39M | -$22M | -$19M |
| Free cash flow | — | — | -$30M | -$57M | -$43M | — | -$45M | -$30M | -$19M | -$15M |
| EPS (diluted) | $-0.56 | $-0.94 | $-0.64 | $-1.06 | $-1.07 | $-1.11 | $-2.24 | $-1.79 | $-1.40 | $-1.65 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -46.6% | -54.9% | -24.9% | -29.5% | -25.3% | -47.4% | -96.0% | -45.8% | -43.3% | -64.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Aldeyra Therapeutics pay a dividend?
Not currently.
Is Aldeyra Therapeutics a good stock to buy?
We do not give buy or sell advice. Aldeyra Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.